Valuation: enGene Therapeutics Inc.

Market Cap 106M 94.53M 87.26M 79.18M 148M 10.05B 151M 1.05B 416M 5.26B 397M 389M 16.6B P/E 2026 *
-0.86x
P/E 2027 * -1.04x
Enterprise Value -78.64M -70.21M -64.8M -58.81M -110M -7.47B -112M -780M -309M -3.91B -295M -289M -12.33B EV / Sales 2026 *
-
EV / Sales 2027 * 5.61x
Free-Float
99.89%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: enGene Therapeutics Inc.

1 day+5.70%
1 week-2.34%
Current month-16.50%
1 month-18.54%
3 months-9.73%
6 months-80.44%
Current year-81.51%
1 week 1.54
Extreme 1.54
1.72
1 month 1.54
Extreme 1.54
2.02
Current year 1.4
Extreme 1.4
12.25
1 year 1.4
Extreme 1.4
12.25
3 years 1.4
Extreme 1.4
47.17
5 years 1.4
Extreme 1.4
47.17
10 years 1.4
Extreme 1.4
47.17
Manager TitleAgeSince
Chief Executive Officer 63 22/07/2024
Director of Finance/CFO 48 16/07/2026
Chief Tech/Sci/R&D Officer 56 15/06/2026
Director TitleAgeSince
Director/Board Member 57 08/08/2023
Director/Board Member 66 18/12/2023
Director/Board Member 66 15/05/2024
Date Insider Type Main position Quantity % Market Cap. Importance
9/22/26 A Buy

Chief Technology Officer

5,102 0.0076%
7/16/26 A Other

Interim Chief Business Officer

75,000 0.1120%
7/16/26 A Other

Chief Financial Officer

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+5.70%-2.34%-79.38%-83.30% 109M
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+3.11%+10.29%+72.56% 54.89B
+0.57%+4.64%+12.82%+89.79% 53.28B
+0.37%+3.07%+28.23%+51.53% 45.81B
-1.21%+0.95%+20.44%+128.58% 43.46B
-0.37%-1.20%+252.94%+568.54% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+4.55%+37.71%+28.10% 23.76B
Average +0.82%+1.00%+36.88%+98.29% 38.2B
Weighted average by Cap. +0.38%+0.56%+48.13%+122.06%

Financials

2026 *2027 *
Net sales - 5.6M 5M 4.61M 4.19M 7.84M 531M 7.96M 55.54M 21.97M 278M 21M 20.55M 878M
Net income -124M -111M -103M -93.09M -174M -11.82B -177M -1.24B -489M -6.19B -467M -457M -19.52B -113M -100M -92.71M -84.13M -158M -10.68B -160M -1.12B -442M -5.59B -422M -413M -17.64B
Net Debt -185M -165M -152M -138M -258M -17.52B -262M -1.83B -724M -9.17B -692M -678M -28.94B -74.46M -66.48M -61.37M -55.69M -104M -7.07B -106M -739M -292M -3.7B -279M -273M -11.68B
Projected Income Statement - Annual - enGene Therapeutics Inc.
Logo enGene Therapeutics Inc.
enGene Therapeutics Inc. is a clinical-stage biotechnology company mainstreaming non-viral genetic medicine through the delivery of therapeutics to mucosal tissues and other organs. The Company's lead program is detalimogene voraplasmid (also known as detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene at high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene is being developed using its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
Employees
-
Date Price Change Volume
23/10/26 $1.560 -1.27% 730,197
22/10/26 $1.580 -3.07% 554,578
21/10/26 $1.630 -2.40% 1,108,892
20/10/26 $1.670 +5.70% 1,119,792
19/10/26 $1.580 -5.39% 783,845
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - enGene Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
1.580USD
Average target price
3.286USD
Spread / Average Target
+107.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - enGene Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. ENGN Stock